Evidence map›Paper›PMID 35322584›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2022

Single-Cell RNA-seq Reveals a Developmental Hierarchy Super-Imposed Over Subclonal Evolution in the Cellular Ecosystem of Prostate Cancer.

Guangzhe Ge, Yang Han, Jianye Zhang, Xinxin Li, Xiaodan Liu, Yanqing Gong, Zhentao Lei, Jie Wang, Weijie Zhu, Yangyang Xu and 7 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Advancements in the Application of scRNA-Seq in Breast Research: A Review.International journal of molecular sciences · 2024
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Guangzhe GeKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, China National Center for Bioinformation, Chinese Academy of Sciences, Beijing, 100101, China.
Yang HanKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, China National Center for Bioinformation, Chinese Academy of Sciences, Beijing, 100101, China.
Jianye ZhangKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, China National Center for Bioinformation, Chinese Academy of Sciences, Beijing, 100101, China.
Xinxin LiKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, China National Center for Bioinformation, Chinese Academy of Sciences, Beijing, 100101, China.
Xiaodan LiuDepartment of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing, 100191, China.
Yanqing GongDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Zhentao LeiDepartment of Urology, Beijing Aerospace Center Hospital, Beijing, 100049, China.
Jie WangDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Weijie ZhuDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Yangyang XuDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Yiji PengDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Jianhua DengDepartment of Urology, Peking Union Medical College Hospital, Beijing, 100730, China.
Bao ZhangDepartment of Urology, Beijing Aerospace Center Hospital, Beijing, 100049, China.
Xuesong LiDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Liqun ZhouDepartment of Urology, Peking University First Hospital, Beijing, 100034, China.
Huiying HeDepartment of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing, 100191, China.
Weimin CiKey Laboratory of Genomics and Precision Medicine, Beijing Institute of Genomics, China National Center for Bioinformation, Chinese Academy of Sciences, Beijing, 100101, China.ORCID 0000-0002-4111-5360

Funding

CAS 202044CAS QYZDB-SSW-SMC039CAS Strategic Priority Research Program XDA16010102Fundamental Research Funds for the Central UniversitiesNational Key R&D Program of China 2018YFC2000100National Key R&D Program of China 2019YFA0110900National Natural Science Foundation of China 82173061Special Projects for Strengthening Basic Research of Peking University BMU2019JC001
6 · The paper itself

Abstract

Prostate cancer (PCa) is a complex disease. An ongoing accumulation of mutations results in increased genetic diversity, with the tumor acquiring distinct subclones. However, non-genetic intra-tumoral heterogeneity, the cellular differentiation state and the interplay between subclonal evolution and transcriptional heterogeneity are poorly understood. Here, the authors perform single-cell RNA sequencing from 14 untreated PCa patients. They create an extensive cell atlas of the PCa patients and mapped developmental states onto tumor subclonal evolution. They identify distinct subclones across PCa patients and then stratify tumor cells into four transcriptional subtypes, EMT-like (subtype 0), luminal A-like (subtype 1), luminal B/C-like (subtype 2), and basal-like (subtype 3). These subtypes are hierarchically organized into stem cell-like and differentiated status. Strikingly, multiple subclones within a single primary tumor present with distinct combinations of preferential subtypes. In addition, subclones show different communication strengths with other cell types within the tumor ecosystem, which may modulate the distinct transcriptional subtypes of the subclones. Notably, by integrating TCGA data, they discover that both tumor cell transcriptional heterogeneity and cellular ecosystem diversity correlate with features of a poor prognosis. Collectively, their study provides the analysis of subclonal and transcriptional heterogeneity and its implication for patient prognosis.

Indexed as

EcosystemProstatic NeoplasmsHumansMaleMutationPrognosisRNA-Seqcellular ecosystemepithelial-to-mesenchymal transitionprostate cancersubtypetranscriptional heterogeneitytumor subclone

Identifiers

PMID35322584
PMCPMC9131431

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.